Gnc-038
Primary Central Nervous System Lymphoma
Explore 71 assets in Primary Central Nervous System Lymphoma →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05485753CT.gov A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Central Nervous System Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gnc-038 (this asset) | Sichuan Baili Pharmaceutical Co., Ltd. | P1/2 | CC · 45 |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BBB |
| (+)-Vincristine | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Orelabrutinib | The First Affiliated Hospital with Nanjing Medical University | P3 | BB |
| Idarubicin | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BB |
| Adriamycin | Juan P. Alderuccio, MD | P4 | BB |
| Cytarabine | The Lymphoma Academic Research Organisation | P4 | BB |
| Dexasone | Allison Winter | P4 | BB |
| Rituximab | Ono Pharmaceutical Co., Ltd. | P4 | BB |
+42 more in the Primary Central Nervous System Lymphoma cohort
Other indications for Gnc-038
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P1/2 | CCC · 48 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P1/2 | CCC · 48 |
| Angioimmunoblastic T-Cell Lymphoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- EtoposideFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBBB
- (+)-VincristineOno Pharmaceutical Co., Ltd.BBB
- OrelabrutinibThe First Affiliated Hospital with Nanjing Medical UniversityBB
- IdarubicinFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBB
- AdriamycinJuan P. Alderuccio, MDBB
Citation
Floatz Terminal. Gnc-038 in Primary Central Nervous System Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gnc-038-primary-central-nervous-system-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →